Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LEUPROLIDE Cause Generalised tonic-clonic seizure? 25 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Generalised tonic-clonic seizure have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.0% of all adverse event reports for LEUPROLIDE.

25
Reports of Generalised tonic-clonic seizure with LEUPROLIDE
0.0%
of all LEUPROLIDE reports
0
Deaths
10
Hospitalizations

How Dangerous Is Generalised tonic-clonic seizure From LEUPROLIDE?

Of the 25 reports, 10 (40.0%) required hospitalization, and 2 (8.0%) were considered life-threatening.

Is Generalised tonic-clonic seizure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 25 reports have been filed with the FAERS database.

What Other Side Effects Does LEUPROLIDE Cause?

Hot flush (9,146) Death (8,772) Intercepted product preparation error (8,621) Syringe issue (7,847) Device leakage (5,861) Wrong technique in product usage process (5,062) Fatigue (4,805) Injection site pain (4,678) Prostatic specific antigen increased (2,432) Asthenia (2,176)

What Other Drugs Cause Generalised tonic-clonic seizure?

LEVETIRACETAM (2,276) LACOSAMIDE (918) LAMOTRIGINE (863) BUPROPION (686) TRAMADOL (496) VENLAFAXINE (427) CARBAMAZEPINE (377) VALPROIC ACID (351) LIDOCAINE (308) PHENYTOIN (307)

Which LEUPROLIDE Alternatives Have Lower Generalised tonic-clonic seizure Risk?

LEUPROLIDE vs LEVALBUTEROL LEUPROLIDE vs LEVAMISOLE LEUPROLIDE vs LEVAQUIN LEUPROLIDE vs LEVEMIR LEUPROLIDE vs LEVETIRACETAM

Related Pages

LEUPROLIDE Full Profile All Generalised tonic-clonic seizure Reports All Drugs Causing Generalised tonic-clonic seizure LEUPROLIDE Demographics